Free tool
Stocks above their 200-day average
We cover 62 companies trading above their own 200-day average. The median market value in the group is $15.75B. Across the group, the median move over the past trading day is +0.80%. 100% of the 62 with a 200-day average trade above it. Price change over the past year runs from −9.5% to +67.1% across the middle 80 percent of the group, with a median of +13.8%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
62 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| GIS.DE | Gilead Sciences, Inc. | $184.35B | Large cap | +33.64% |
| PFE.DE | Pfizer Inc. | $161.11B | Large cap | +22.96% |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% |
| BRM.DE | Bristol-Myers Squibb Company | $137.92B | Large cap | +50.84% |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% |
| MRK.DE | Merck KGaA | $70.28B | Large cap | +32.17% |
| 0QF.DE | Moderna, Inc. | $59.07B | Large cap | +550.51% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.25B | Large cap | +76.91% |
| BAY.WA | Bayer Aktiengesellschaft | $55.90B | Large cap | +76.59% |
| EWL.DE | Edwards Lifesciences Corporation | $52.39B | Large cap | +11.65% |
| BOX.DE | Becton, Dickinson and Company | $51.84B | Large cap | +1.73% |
| SHL.DE | Siemens Healthineers AG | $51.23B | Large cap | −14.18% |
| H6D0.DE | Haleon plc | $44.85B | Large cap | +5.39% |
| HLN.L | Haleon plc | $44.62B | Large cap | +2.68% |
| QTS.DE | IQVIA Holdings Inc. | $43.01B | Large cap | −4.04% |
| VEE.DE | Veeva Systems Inc. | $40.02B | Large cap | +13.43% |
| ILU.DE | Illumina, Inc. | $34.08B | Large cap | +129.80% |
| DC4.DE | DexCom, Inc. | $33.35B | Large cap | +21.06% |
| IDP.DE | Biogen Inc. | $32.39B | Large cap | +65.32% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.43B | Large cap | +1.64% |
| 22UA.DE | BioNTech SE | $28.28B | Large cap | +14.09% |
| MTO.DE | Mettler-Toledo International Inc. | $27.92B | Large cap | +13.15% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.68B | Large cap | +25.88% |
| VIA.DE | Viatris Inc. | $19.41B | Large cap | +67.32% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% |
| ESF0.DE | Eurofins Scientific SE | $14.67B | Large cap | +12.65% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% |
| ORNAV.HE | Orion Oyj | $13.11B | Large cap | +21.27% |
| FME.DE | Fresenius Medical Care AG | $12.64B | Large cap | −2.61% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −5.53% |
| KRK.WA | Krka, d. d. | $9.20B | Mid cap | +30.59% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +8.99% |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% |
| CTEC.L | Convatec Group PLC | $6.01B | Mid cap | −1.95% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.61B | Mid cap | −9.62% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| MCOV-B.ST | Medicover AB (publ) | $3.85B | Mid cap | −8.20% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| AFX.DE | Carl Zeiss Meditec AG | $3.19B | Mid cap | −24.83% |
| BIOA-B.ST | BioArctic AB (publ) | $3.00B | Mid cap | +12.31% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.